How a patient association gave rise to a company

Last updated: June 24, 2024

A patient association in rare diseases is first and foremost families who all have one thing in common: they need a cure to be found and made available.

Discover how French company AtmosR worked with a patient association to tackle the need to find a cure for Ondine:

Subscribe to our newsletter

Kayentis publishes its first ESG report, strengthening its commitment to...

Kayentis launches interactive eConsent solution to simplify and improve patient...

Better Raters,Smarter eCOA,Stronger Data

Strengthening Endpoint Reliability: An Interview with Estelle Haenel, Chief Medical...

Kayentis and RWS join forces to improve data confidence in...

What if eCOA could elevate your next rare disease trial?

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events